LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Most Cited Paper
in Virus-based gene therapy research
18 Months Post-Publication
Class of 2026
“LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026/
Topics
LOAd703 · Oncolytic virus · Immunostimulatory gene therapy · pancreatic cancer · unresectable pancreatic cancer · metastatic pancreatic cancer · LOKON001 · phase 1/2 trial · Combination therapy · chemotherapy combination · Intratumoral injection · tumor-directed therapy · immune activation
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Virus-based gene therapy research Papers, Class of 2026. https://pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459